R&D project on psilocybin’s benefits in treating diseases of the brain VANCOUVER, BC, Nov. 30, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased and extremely grateful to acknowledge the financial contribution from the Government of Canada towards an important component of its research and development into the positive effects of psilocybin on…


Previous articleRed Light Holland Reports Second Quarter 2021 Results
Next articlePT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your Symphony of Selves